Back to search

Article

Multiple effects of TNFα inhibitors on the development of the adaptive immune response after SARS-CoV-2 vaccination

2022-07-03

Abstract excerpt

<h4>Objectives</h4> The humoral immune response to SARS-CoV-2 vaccination in patients with chronic inflammatory disease (CID) declines more rapidly with TNFα inhibition. Furthermore, the efficacy of current vaccines against Omicron variants of concern (VOC) including BA.2 is limited. Alterations within immune cell populations, changes in IgG affinity and the ability to neutralise a pre-VOC strain and the BA.2 vir...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
3545a3e3-1252-5cf1-896d-a2b8ec2c8433
DOI
10.1101/2022.07.01.22277143
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Multiple effects of TNFα inhibitors on the development of the adaptive immune response after SARS-CoV-2 vaccinationDOI 10.1101/2022.07.01.22277143
Accelerated waning of immunity to SARS-CoV-2 mRNA vaccines in patients with immune mediated inflammatory diseasesSemantic proximity
Third and fourth vaccine doses broaden and prolong immunity to SARS-CoV-2 in immunocompromised adult patientsSemantic proximity
Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boostersSemantic proximity
Reduced antibody activity against SARS-CoV-2 B.1.617.2 Delta virus in serum of mRNA-vaccinated patients receiving TNF-α inhibitorsSemantic proximity
Anti-SARS-CoV-2 immunogenicity decay and incident cases six months after Sinovac-CoronaVac inactivated vaccine in autoimmune rheumatic diseases patients: phase 4 prospective trialSemantic proximity
Favourable vaccine-induced SARS-CoV-2 specific T cell response profile in patients undergoing immune-modifying therapiesSemantic proximity
Immunogenicity and Safety of the Booster BNT162b2 Vaccine in Patients with Axial Spondyloarthritis Treated with Biological Disease-Modifying DrugsSemantic proximity
Immunogenicity and safety of an inactivated virus vaccine against SARS-CoV-2 in patients with autoimmune rheumatic diseasesSemantic proximity
Examining the Immunological Effects of COVID-19 Vaccination in Patients with Conditions Potentially Leading to Diminished Immune Response Capacity – The OCTAVE TrialSemantic proximity
Methotrexate and Tumor Necrosis Factor Inhibitors Independently Decrease Neutralizing Antibodies after SARS-CoV-2 Vaccination: Updated Results from the SUCCEED StudySemantic proximity
Effects of the Second Dose of COVID-19 Vaccines in Patients with Autoimmune Rheumatic Diseases with Hybrid ImmunitySemantic proximity
Immune responses and disease biomarker long-term changes following COVID-19 mRNA vaccination in a cohort of rheumatic disease patientsSemantic proximity
Select a neighboring publication to make it the new centre.